Zevra Therapeutics Reports Strong FY25 Profitability & Robust Cash Position, Appoints New CFO
ZVRA sits 78% above its 52-week low of $6.19 on elevated volume (1.8× avg).
Summary
Zevra Therapeutics announced a significant financial turnaround for fiscal year 2025, reporting substantial net income and a strong cash position, alongside the appointment of Justin Renz as Chief Financial Officer.
Key Events · Earnings and Guidance · ZVRA
-
Achieved Significant Profitability
Reported FY25 net income of $83.2 million, a substantial improvement from a $105.5 million net loss in FY24, with Q4 2025 net income of $12.2 million.
-
Strong Revenue Growth
FY25 net revenue reached $106.5 million, up from $23.6 million in FY24, driven by MIPLYFFA net revenue of $87.4 million.
-
Robust Cash Position
Ended FY25 with $238.9 million in cash, cash equivalents, and securities, indicating strong financial flexibility and independence from capital markets.
-
New Chief Financial Officer Appointed
Justin Renz, an experienced biopharmaceutical financial executive, was appointed CFO and Treasurer, effective March 9, 2026. This follows a prior press release on March 5, 2026.
Analysis · ZVRA · Life Sciences
Zevra Therapeutics delivered a remarkable financial performance in fiscal year 2025, shifting from a significant net loss in 2024 to a net income of $83.2 million. This substantial turnaround, coupled with a robust cash balance of $238.9 million, significantly strengthens the company's financial foundation and provides independence from capital markets. The company's statement about having sufficient resources to execute strategic priorities without needing capital markets is a strong positive signal. The appointment of an experienced CFO, Justin Renz, further supports the company's strategic growth initiatives. Investors should view these results as a strong indicator of operational success and improved financial health.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZVRA was trading at $11.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $513.4M. The 52-week trading range was $6.19 to $13.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.